Table 1 Characteristics of included studies
Author (year) | Country | Study design | Age (years)* | Duration of wet AMD (months)* | Regimen | Sample (N) | BCVA at baseline (ETDRS)* | Mean change BCVA at 12-months (ETDRS) | Mean change CMT (μm) | Total injections* | Total hospital visits* | Adverse events (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Weber (2020) | France | RCT | 79.6 ± 7.9 | 1.4 ± 8.7 | Bimonthly | 102 | 57.3 ± 17.9 | + 7.6 | n/a | 7.2 ± 0.8 | 9.5 ± 1.8 | 5 |
Pro re nata | 60 | 56 ± 24.3 | + 0.1 | n/a | 5.2 ± 1.8 | 8.8 ± 1.8 | 2 | |||||
Veritti (2019) | Italy | RCT | 77.3 ± 7.0 | n/a | Bimonthly | 92 | 56 ± 13.9 | + 6.7 | − 97.362 | 7 | 4 | n/a |
78.2 ± 6.2 | Pro re nata | 92 | 53.4 ± 15.2 | + 1.9 | − 55.462 | 5.5 ± 1.6 | 12 | |||||
Mori (2017) | Japan | RCT | 72.8 ± 2.59 | n/a | Bimonthly | 28 | 65.75 ± 4.53 | + 7.1 | − 116.333 | 7 | 12 | n/a |
76.5 ± 2.64 | Pro re nata | 30 | 67.43 ± 4.59 | + 3.4 | − 101.333 | 4.8 ± 1.5 | 12 | |||||
Keppi (2017) | France | Retro-spective | 78.4 (61–95) | n/a | Bimonthly | 19 | 57.2 (20–72) | + 8.4 | − 113.333 | 7.5 | 4 | n/a |
85.2 (62–93) | Pro re nata | 15 | 58.4 (28–80) | − 0.4 | − 105.333 | 7.6 (3–11) | 7.8 (6–11) |